A share price of Sarepta Therapeutics Inc [SRPT] is currently trading at $124.06, up 0.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SRPT shares have gain 1.69% over the last week, with a monthly amount drifted -7.84%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, Sarepta Therapeutics to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on January 31, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $170. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $109 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $224 on November 21, 2023. Oppenheimer downgraded its rating to a Perform. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 31, 2023, and downed its price target to $40. In a note dated June 23, 2023, Evercore ISI downgraded an In-line rating on this stock but restated the target price of $139.
Sarepta Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $55.25 and $159.89. Currently, Wall Street analysts expect the stock to reach $148.67 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $124.06 at the most recent close of the market. An investor can expect a potential return of 19.84% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Trailing Twelve Months sales for Sarepta Therapeutics Inc [NASDAQ:SRPT] were 1.24B which represents 53.54% growth. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.42%, and Net Profit Margin reading is -0.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.7 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 122.61 points at the first support level, and at 121.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.56, and for the 2nd resistance point, it is at 127.05.
Sarepta Therapeutics Inc [SRPT] reported earnings per share of $0.47 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.01/share, meaning a difference of $0.46 and a surprise factor of 4,600.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$1.23 per share, a difference of $0.77 representing a surprise of 62.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sarepta Therapeutics Inc [NASDAQ:SRPT] is 3.95. Also, the Quick Ratio is 3.45, while the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 9.37, the price to book ratio is 13.53.
Transactions by insiders
Recent insider trading involved Boor Kathryn Jean, Director, that happened on Mar 11 ’24 when 761.0 shares were sold. Director, Wigzell Hans Lennart Rudolf completed a deal on Mar 08 ’24 to sell 15000.0 shares. Meanwhile, Director Mayo Stephen sold 3135.0 shares on Mar 05 ’24.
